<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322632</url>
  </required_header>
  <id_info>
    <org_study_id>280-01</org_study_id>
    <nct_id>NCT02322632</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions</brief_title>
  <official_title>An Open-label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Paricalcitol Capsules 4 mcg of Dr. Reddy's Laboratories Limited and Zemplar Capsules, 4 mcg of Abbott Laboratories, USA in Healthy, Adult, Human Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose,&#xD;
      crossover oral bioequivalence study in healthy subjects under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose,&#xD;
      crossover oral bioequivalence study of Paricalcitol Capsules 4 mcg of Dr. Reddy's&#xD;
      Laboratories Limited and Zemplar® Capsules 4 mcg of Abbott Laboratories, USA in healthy,&#xD;
      adult, human subjects under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve</measure>
    <time_frame>0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0 and 60.0 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Paricalcitol Capsules, 4 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zemplar Capsules, 4 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zemplar Capsules, 4 mcg of Abott Laboratories USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol Capsules, 4 mcg</intervention_name>
    <description>Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Paricalcitol Capsules, 4 mcg</arm_group_label>
    <arm_group_label>Zemplar Capsules, 4 mcg</arm_group_label>
    <other_name>Zemplar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, adult, human volunteers between 18 and 55 years of age (both inclusive)&#xD;
             living in and around Ahmedabad city of western part of India.&#xD;
&#xD;
          -  Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as&#xD;
             weight in kg/height in m2.&#xD;
&#xD;
          -  Have no significant diseases or clinically significant abnormal findings during&#xD;
             screening, medical history, clinical examination, laboratory evaluations, 12- lead ECG&#xD;
             and X-ray chest (postero-anterior view) recordings.&#xD;
&#xD;
          -  Volunteers who have normal calcium, phosphorous status and no hypertensive status in&#xD;
             order to avoid effect on vitamin D concentration in blood.&#xD;
&#xD;
          -  Able to comply with the study procedures, in the opinion of the Principal&#xD;
             investigator.&#xD;
&#xD;
          -  Able to give voluntary informed consent for participation in the trial.&#xD;
&#xD;
        In case of female subjects*:&#xD;
&#xD;
          -  Surgically sterilized at least 6 months prior to study participation; Or&#xD;
&#xD;
          -  If of child bearing potential is willing to use a suitable and effective double&#xD;
             barrier contraceptive method or intra uterine device during the study.&#xD;
&#xD;
          -  Urine pregnancy test (for female subjects*) must be negative at the time of screening.&#xD;
             *No female subjects were enrolled in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or idiosyncratic reaction to Paricalcitol or to any of its&#xD;
             excipients or any drug or any substance.&#xD;
&#xD;
          -  History or presence of any disease or condition which might compromise the&#xD;
             haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular,&#xD;
             immunological, dermatological, gastrointestinal or any other body system.&#xD;
&#xD;
          -  Ingestion or Use of any medication at any time in 14 days prior to dosing. In any such&#xD;
             case subject selection will be at the discretion of the Principal Investigator.&#xD;
&#xD;
          -  Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or&#xD;
             NSAID induced urticaria.&#xD;
&#xD;
          -  Consumption of Grapefruits or its products within a period of 48 hours prior to&#xD;
             check-in.&#xD;
&#xD;
          -  A recent history of harmful use of alcohol(less than 2 years), i.e. alcohol&#xD;
             consumption of more than 14 standard drinks per week for men and more than 7 standard&#xD;
             drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of&#xD;
             wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc). &quot; or&#xD;
             consumption of alcohol or alcoholic products within 48 hous prior to check-in.&#xD;
&#xD;
          -  Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from&#xD;
             smoking during the study.&#xD;
&#xD;
          -  The presence of clinically significant abnormal laboratory values during screening.&#xD;
&#xD;
          -  Use of any recreational drugs or history of drug addiction or testing positive in&#xD;
             pre-study drug scans.&#xD;
&#xD;
          -  History or presence of psychiatric disorders.&#xD;
&#xD;
          -  A history of difficulty with donating blood.&#xD;
&#xD;
          -  Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal&#xD;
             product or participation in a drug research study within a period of 90 days prior to&#xD;
             the first dose of study medication. Elimination half-life of the study drug should be&#xD;
             taken into consideration for inclusion of the subject in the study. Note: In case the&#xD;
             blood loss is ≤ 200 mL, subject may be enrolled 60 days after blood donation or last&#xD;
             sample of the previous study.&#xD;
&#xD;
          -  A positive hepatitis screen including hepatitis B surface antigen and anti- HCV&#xD;
             antibodies.&#xD;
&#xD;
          -  A positive test result for anti-HIV antibody.&#xD;
&#xD;
          -  An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to&#xD;
             receiving the study drug and throughout the subjects' participation in the study. In&#xD;
             any such case subject selection will be at the discretion of the Principal&#xD;
             Investigator. Nursing mothers (females)*. *No female subjects were enrolled in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Pankaj Kumar Jha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>3 80 061</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

